Applications and Challenges of Oral Peptide Drug Delivery in Diabetes Treatment

Yuchen Feng

doi:10.54254/2753-8818/2025.20300

Research Article

Open access

Published on 13 January 2025

Download pdf

Feng,Y. (2025). Applications and Challenges of Oral Peptide Drug Delivery in Diabetes Treatment. Theoretical and Natural Science,68,234-244.

Export citation

Applications and Challenges of Oral Peptide Drug Delivery in Diabetes Treatment

Yuchen Feng *^,1,

¹ University College of London

* Author to whom correspondence should be addressed.

https://doi.org/10.54254/2753-8818/2025.20300

Abstract

Peptide drugs, an important class of biopharmaceuticals, have been studied and applied in the field of diabetes treatment for decades. In recent years, with a deeper understanding of the physiological mechanisms of diabetes, efforts by developers to improve therapeutic efficacy have increased. Although oral administration is the most common mode of drug delivery, many peptide drugs still need to be administered by injection due to their unique chemical structures and biological properties. The paper aims to summarize the research literature related to diabetes and analyze the major barriers to the development of oral peptide drugs, such as the stability and low bioavailability of peptides in the GI tract, as well as technological coping strategies to address these barriers, including novel delivery systems and formulation optimization. In addition, it assesses the current progress in the development of oral peptide drugs and their clinical applications, mainly with reference to relevant literature from 2015 onwards. The results indicate that although some oral peptide drugs have been approved, the possibility of their popularization is still relatively small in the short term. Thus, future research should focus on overcoming the technical challenges of oral drug delivery in order to enhance their clinical application potential and ultimately provide patients with more convenient and effective treatment options

Keywords

Oral Peptide Drug Delivery, Diabetes Treatment, Bioavailability, Nanoparticles, Permeation Enhancers

View pdf

References

[1]. Sapra, A. and Bhandari, P. (2023) Diabetes.In: StatPearls [Internet]. Treasure Island (FL): StatPearls.

[2]. Karamanou, M., Protogerou, A., Tsoucalas, G., Androutsos, G. and Poulakou-Rebelakou, E. (2016) Milestones in the history of diabetes mellitus: The main contributors. World J. Diabetes, 7: 1-7.

[3]. World Health Organization. (n.d.) Diabetes. https://www.who.int/health-topics/diabetes.

[4]. Ong, K.L. et al. (2023) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet 402, 203-234.

[5]. Word Health Organization. (n.d.) Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes.

[6]. Wilcox, G.(2005) Insulin and Insulin Resistance. Clin. Biochem. Rev. 26, 19-39.

[7]. Rashid, A. and Xie, V. (2024) Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics. https://xtalks.com/top-15-diabetes-drugs-in-2023-by-2022-sales-statistics-3715/.

[8]. Ahrén, B. (2011) GLP-1 for type 2 diabetes. Exp. Cell Res. 317, 1239-1245 (2011).

[9]. Sheahan, K.H., Wahlberg, E.A. and Gilbert, M.P. (2010) An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad. Med. J. 96, 156-161.

[10]. Collins, L. and Costello, R.A. (2024) Glucagon-Like Peptide-1 Receptor Agonists. In: StatPearls [Internet], Treasure Island (FL).

[11]. Tyagi, P., Pechenov, S. and Anand Subramony, J. (2018) Oral peptide delivery: Translational challenges due to physiological effects. J. Controlled Release 287, 167-176.

[12]. Zizzari, A.T., et al. (2021) New perspectives in oral peptide delivery. Drug Discov. Today 26, 1097-1105.

[13]. Saffran, M., et al. (2011) A model for the study of the oral administration of peptide hormones. Can. J. Biochem.

[14]. Alqahtani, M.S., et al. (2021) Advances in Oral Drug Delivery. Front. Pharmacol. 12, 618411.

[15]. Richter, B. and Neises, G. (2005) Human’ insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst. Rev., CD003816.

[16]. Kramer, C.K., Retnakaran, R. and Zinman, B. (2021) Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials. Cell Metab. 33, 740-747.

[17]. Baeshen, N.A., et al. (2014) Cell factories for insulin production. Microb. Cell Factories 13, 141.

[18]. Heller, S., et al. (2013) Meta-analysis of insulin aspart versus regular human insulin used in a basal–bolus regimen for the treatment of diabetes mellitus. J. Diabetes 5, 482-491.

[19]. Mapelli, C., et al. (2009) Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity. J. Med. Chem. 52, 7788-7799.

[20]. Sjöholm Å. (2010) Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs. Pharmaceuticals (Basel). 3(3): 764-781.

[21]. Damholt, A.B., Kofod, H. and Buchan, A.M.J. (1999) Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res. 298, 287-293.

[22]. Gupta, V. (2013) Glucagon-like peptide-1 analogues: An overview. Indian J. Endocrinol. Metab. 17, 413.

[23]. Kalra, S. and Sahay, R. (2020) A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. Diabetes Ther., 11(9): 1965-1982.

[24]. Aroda, V.R., Blonde, L. and Pratley, R.E. (2022) A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Rev. Endocr. Metab. Disord. 23, 979-994.

[25]. Scitable. (2010) Enzyme Catalysis: The Serine Proteases www.nature.com/scitable/topicpage/enzyme-catalysis-the-serine-proteases-14398894.

[26]. Ahmad, A. and Khan, J.M. (2022) pH-sensitive endosomolytic peptides in gene and drug delivery: Endosomal escape and current challenges. J. Drug Deliv. Sci. Technol. 76, 103786.

[27]. Britannica, T. (2024) pH. Encyclopedia Britannica. https://www.britannica.com/science/pH

[28]. Lee, Y.H. et al. (1999) Impact of Regional Intestinal pH Modulation on Absorption of Peptide Drugs: Oral Absorption Studies of Salmon Calcitonin in Beagle Dogs. Pharm. Res. 16, 1233-1239.

[29]. Hadji, H. and Bouchemal, K. (2022) Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems. Adv. Drug Deliv. Rev. 181, 114101.

[30]. Russell, T.L., et al. (1993) Upper Gastrointestinal pH in Seventy-Nine Healthy, Elderly, North American Men and Women. Pharm. Res. 10, 187-196.

[31]. Queckenberg, C. and Fuhr U. (2009) Influence of posture on pharmacokinetics. Eur. J. Clin. Pharmacol. 65.

[32]. Akbarian, M. and Chen, S.H. (2022) Instability Challenges and Stabilization Strategies of Pharmaceutical Proteins. Pharmaceutics 14, 2533.

[33]. Wang, X.Q. and Zhang, Q. (2012) pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 82, 219-229.

[34]. Mitragotri, S., Burke, P.A. and Langer, R. (2014) Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat. Rev. Drug Discov. 13, 655-672.

[35]. Lewis, A.L., McEntee, N., Holland, J. et al. (2022) Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery. Drug Deliv. and Transl. Res. 12, 1-6.

[36]. Li, Y., et al. (2022) Advances in oral peptide drug nanoparticles for diabetes mellitus treatment. Bioact. Mater. 15, 392-408.

[37]. Turner, P.V., et al. (2011) Administration of Substances to Laboratory Animals: Routes of Administration and Factors to Consider. J. Am. Assoc. Lab. Anim. Sci. JAALAS 50, 600-613.

[38]. Joudeh, N. and Linke, D. (2022) Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists. J. Nanobiotechnology 20, 262.

[39]. Gelperina, S., Kisich, K., Iseman, M.D. and Heifets, L. (2005) The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. Am. J. Respir. Crit. Care Med. 172, 1487-1490.

[40]. Cao, S., et al. (2019) Nanoparticles: Oral Delivery for Protein and Peptide Drugs. AAPS PharmSciTech 20, 190.

[41]. Wang, M., et al. (2014) Permeability of Exendin-4-Loaded Chitosan Nanoparticles across MDCK Cell Monolayers and Rat Small Intestine. Biol. Pharm. Bull. 37, 740-747.

[42]. ABP Biosciences. (n.d.) Lipid Nanoparticles (LNPs). www.abpbio.com/product/lipid-nanoparticles-lnps/.

[43]. Zielińska, A., et al. (2020) Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology. Molecules 25, 3731.

[44]. Lin, P., et al. (2018) Oral Nonviral Gene Delivery for Chronic Protein Replacement Therapy. Advanced Science, 5.

[45]. Shan, W. et al. (2015) Overcoming the Diffusion Barrier of Mucus and Absorption Barrier of Epithelium by Self-Assembled Nanoparticles for Oral Delivery of Insulin. ACS nano, 9(3): 2345-2356.

[46]. Poscher, V. and Salinas Y. (2020) Trends in Degradable Mesoporous Organosilica-Based Nanomaterials for Controlling Drug Delivery: A Mini Review. Materials (Basel).

[47]. Araújo, F., et al. (2015) Microfluidic Assembly of a Multifunctional Tailorable Composite System Designed for Site Specific Combined Oral Delivery of Peptide Drugs. ACS Nano 9: 8291-8302.

[48]. Zhou, Y., et al. (2020) A Nanocomposite Vehicle Based on Metal-Organic Framework Nanoparticle Incorporated Biodegradable Microspheres for Enhanced Oral Insulin Delivery. ACS Appl. Mater. Interfaces 12, 22581-22592.

[49]. Abramson, A., et al. (2019) A luminal unfolding microneedle injector for oral delivery of macromolecules. Nat. Med. 25: 1512-1518.

[50]. Yan, Q., et al. (2021) Finite Element Analysis for Biodegradable Dissolving Microneedle Materials on Skin Puncture and Mechanical Performance Evaluation. Polymers 13, 3043.

[51]. Zhu, Y., Ye, J. and Zhang, Q. (2020) Self-emulsifying Drug Delivery System Improve Oral Bioavailability: Role of Excipients and Physico-chemical Characterization. Pharm. Nanotechnol. 8, 290-301.

[52]. Leonaviciute, G. and Bernkop-Schnürch, A. (2015) Self-emulsifying drug delivery systems in oral (poly)peptide drug delivery. Expert Opin. Drug Deliv.

[53]. Li, P., et al. (2013) Preparation and characterization of insulin-surfactant complexes for loading into lipid-based drug delivery systems. J. Pharm. Sci. 102: 268-2698.

[54]. Qi, X., et al. (2011) Self-double-emulsifying drug delivery system (SDEDDS): a new way for oral delivery of drugs with high solubility and low permeability. Int. J. Pharm. 409: 245-251.

[55]. Friedl, H. et al. (2013) Development and evaluation of a novel mucus diffusion test system approved by self-nanoemulsifying drug delivery systems. J. Pharm. Sci. 102: 4406-441.

[56]. Ahn, S. et al. (2013) Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. J. Controlled Release 170: 226-232.

[57]. Kim, J.C., Park, E.J. and Na, D.H. (2022) Gastrointestinal Permeation Enhancers for the Development of Oral Peptide Pharmaceuticals. Pharmaceuticals, 15: 1585.

[58]. Bækdal, T.A., et al. (2021) Relationship Between Oral Semaglutide Tablet Erosion and Pharmacokinetics: A Pharmacoscintigraphic Study. Clin. Pharmacol. Drug Dev. 10: 453-462.

[59]. European Medicines Agency. (n.d) Rybelsus. www.ema.europa.eu/en/medicines/human/EPAR/rybelsus.

[60]. Brayden, D.J. and Maher, S. (2021) Transient Permeation Enhancer® (TPE®) technology for oral delivery of octreotide: a technological evaluation. Expert Opin. Drug Deliv. 18: 1501-1512.

[61]. Wang, J., Yadav, V., Smart, A.L., Tajiri, S. and Basit, A.W. (2015) Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Mol. Pharm. 12: 966-973.

[62]. MyCapssa. (n.d) What is MyCapssa. https://mycapssa.com/patients/what-is-mycapssa.

[63]. Sadeghi, A.M.M. et al. (2008) Permeation enhancer effect of chitosan and chitosan derivatives: Comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 70: 270-278.

[64]. Wong, C.Y., Al-Salami, H. and Dass, C.R. (2018) The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation. J. Drug Target.

[65]. Qinna, N.A. et al. (2015) Influence of Molecular Weight and Degree of Deacetylation of Low Molecular Weight Chitosan on the Bioactivity of Oral Insulin Preparations. Mar. Drugs 13: 1710-1725.

[66]. Knudsen, L.B. and Lau, J. (2019) The Discovery and Development of Liraglutide and Semaglutide. Front. Endocrinol. 10.

[67]. Kratz, F. (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Contro Release, 132: 171-183.

Cite this article

Feng,Y. (2025). Applications and Challenges of Oral Peptide Drug Delivery in Diabetes Treatment. Theoretical and Natural Science,68,234-244.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 3rd International Conference on Modern Medicine and Global Health

Conference website: https://2025.icmmgh.org/

ISBN：978-1-83558-767-6(Print) / 978-1-83558-768-3(Online)

Conference date: 10 January 2025

Editor：Sheiladevi Sukumaran

Series: Theoretical and Natural Science

Volume number: Vol.68

ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).